Forgot Password

Thank you for your request!

We will soon reach out to you.

Thank you for downloading..!

Contact us for more information.
Home » Healthcare » Pharmaceuticals » HPH-6070717

  • Global DNA Vaccine Market Insights, Opportunity Analysis, Market Shares and Forecast 2017 – 2023

  • Publish: June 2017 | Report Code: HPH-6070717

* For discount/customization and buying a particular chapter click here or write to us at [email protected]

DNA vaccines are one of the type of third generation vaccines that are based on the purified plasmid preparation that contains transgenes which is capable of encoding antigenic proteins that triggers an immune response against the infectious diseases. DNA Vaccine technology has numerous advantages over other traditional vaccination and therapeutics techniques in terms of ease of fabrication, efficacy, safety and stability. As of year 2016, human related applications of DNA vaccines are under clinical trials, however animal DNA vaccines are available in commercial market. Global DNA vaccine market is anticipated to rise with a CAGR of about 55% during the forecast years 2016-2023. Increase in the clinical trials of DNA based vaccine for the treatment of infectious diseases can be observed in the market. For example, National Institute of Allergy and Infectious Diseases (NIAID), a part of national institute of health is leading a clinical trials for DNA based vaccine and aims to include total of 2,490 healthy participants in those areas where a confirmed or potential active mosquito-transmitted Zika infection has been recorded. These areas includes the United States, Brazil, Puerto Rico, Costa Rica, Peru, Panama and Mexico. Surging investments in the development of third generation vaccination technology is driving  global DNA vaccines market. Some other factors that includes rising prevalence of chronic and infectious diseases, increasing adoption of DNA vaccines for animal healthcare and low cost of DNA vaccines as compared to other gene therapy technologies also helps to increase the market growth.

Fast growth projected in the DNA vaccination market once they get approval in clinical trials has attracted majority of investors to deviate their investments for strong returns. About 100 clinical trials are in the progress for humans for the wide range of diseases that includes Cancer, HIV, Hepatitis, zika infection, influenza and other infectious diseases.  The Melinda gates foundation has provided a fund of about $100 million to the Moderna therapeutics for the development of DNA vaccines for the infectious disease. Furthermore, government departments are also funding the development of DNA vaccines to the private companies. For instance, US department of health and services agreed to provide a fund of about $125 million to the Moderna therapeutics for the development of vaccine for Zika infection. Similarly, HIV vaccine and trial network provided a funding of $23.5 million to the Inovio for the development of Pennvax-B. These investments has propelled the growth in research and development activities of the DNA vaccine market.

The report on global DNA vaccine market includes DNA Vaccine type, technology and application.

DNA vaccine type are segmented into:

  • Animal DNA vaccines
  • Human DNA vaccines



DNA vaccine technologies are segmented into:

  • Plasmid DNA vaccines technology
  • Plasmid DNA delivery technology



The applications of DNA vaccines market include:

  • Human disease applications


o   Oncology

o   Infectious diseases

o   Allergies

o   Others

  • Veterinary disease applications


o   Canine melanoma

o   Leishmaniasis

o   Equine West Nile Virus

o   Others

The report scope is widely categorized on the basis of sales of animal DNA vaccines along with current investments in research and clinical trials of human DNA vaccines. As there is no product for human DNA vaccine in the market for sale as of year 2016, the report excludes any real-time revenue figure from sales and its forecast in human segment by type. The report widely covers DNA vaccine technologies and delivery technologies. Viral vector vaccines have also been excluded from the scope of study.

The global DNA vaccine market report has been geographically segmented into:

  • North America (U.S. & Canada)
  • Asia Pacific (China, India, Japan and RoAPAC)
  • Europe (UK, France, Germany, Spain and RoE)
  • Rest of World





North America region dominates the market among other regions. Increasing prevalence of infectious and chronic diseases in countries such as the US and Canada is driving the demand of effective vaccination technology. Mortality rate due to chronic and infectious disease has increased in United States to about 360,000 every year. Furthermore, interest of governments agencies such as National institute of health, National institute of allergy and infectious disease and others in the development of DNA based vaccines has also helped to promote the market growth in the United States. Asia pacific market is anticipated to be the fastest growing region due to rising awareness among consumers regarding the advantages of immunization in case of Hepatitis B and H1N1 influenza. In countries such as China, state food and drug administration designated 11 biotech companies for the H1N1 vaccines. These companies include Sinovac, Haiwang interlong, SIBS, Hualan Bio and others.

Among the segment of DNA vaccine type, Animal DNA vaccine is a leading the market due to unavailability of human DNA vaccines in the market along with rising incidence of canine melanoma and other animal diseases. Canine melanoma accounts to about 7% of all canine skin tumours cases globally. Moreover, after the entry of human DNA vaccines, this segment is expected to grow at a fast pace. Among the application segment, the veterinary applications are leading the market due to availability of DNA vaccines for animal diseases that includes canine melanoma vaccine (DOG), West Nile Innovator (Horse), Life tide-SW5 (Swine and other food animals) and Apex-IHN (Salmon fish).  

The major market players of the global DNA vaccine market are:

  • Novartis Animal Health
  • Inovio Biomedical Corp.
  • Merck & Co.
  • Vical Inc.
  • Others






These companies using various strategies such as merger & acquisition, collaboration, partnership and product launch. Whereas, merger & acquisition is the key strategy adopted by the companies in the global DNA vaccine market.

For example, On 10th August 2015, the global biological research and development arm of AstraZeneca, Medimmune entered into a licence agreement and cancer vaccine collaboration with Inovio Pharmaceuticals.  The agreement covers clinical stage cancer vaccine INO-3112 HPV and collaboration for preclinical development of additional cancer vaccine candidates. Under the agreement, Medimmune has been granted with an exclusive rights for INO-3112 immunotherapy of Inovio pharmaceutical that targets the cancer causing human papilomavirus of type 16 and 18. The INO-3112 is under the clinical trials for head, neck and cervical cancers. This vaccine works by generating a response of killer T cell that destroys tumours driven by Human papilomavirus type16 and 18.

Key reason to buy the report:

  • The report includes market estimation, forecast and analysis for the year 2016-2023
  • Report includes detailed analysis of different segments such as DNA vaccines type, technology and applications in DNA vaccine market.
  • Identify and understand the strength, opportunities, challenges and threat of the DNA Vaccines market.
  • Covers details analysis of Porters 5 force model and other strategic models and also covers revenues, market share analysis, and competitive landscape analysis of major players of DNA vaccine market.
  • Detailed analysis of various the regulatory policies which are affecting the global DNA vaccine market.






How we are different from others:

At Occam’s we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global DNA vaccine market offers detailed analysis of strategic models such as investment vs. adoption model, see saw analysis and others strategic models. Also, the report contains the detailed analysis of application, adoption scenario and decision support for each segment. The report discusses competitive landscape of the DNA vaccine market, with giving extensive SCOT analysis of key companies. 

Key findings of the global DNA Vaccine market.

  • Surging investments in the development of third generation vaccination technology is driving strong growth in the global DNA vaccine market.
  • North America held highest revenue share in 2016.
  • Animal DNA Vaccine segment holds the largest market among DNA Vaccination type segments due to increase in animal oriented cancer diseases globally.
  • Collaboration and agreements are the key strategy adopted by the market players of DNA vaccine market. 
1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
 
2. MARKET OVERVIEW
2.1. GLOBAL DNA VACCINES MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION AND SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360 DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES AND ANALYSIS
2.8.2. MARKET SHARE AND TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
 
3. MARKET DETERMINANTS 
3.1. MARKET DRIVERS
3.1.1. RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES
3.1.2. SURGING INVESTMENTS IN THE DEVELOPMENT OF THIRD GENERATION VACCINATION TECHNOLOGY
3.1.3. INCREASING ADOPTION OF DNA VACCINES FOR ANIMAL HEALTHCARE 
3.1.4. LOW COST OF DNA VACCINES AS COMPARED TO OTHER GENE THERAPY TECHNOLOGIES.
3.2. MARKET RESTRAINTS
3.2.1. STRINGENT GOVERNMENT RULES AND REGULATIONS
3.2.2. LACK OF LEGAL AND ETHICAL FRAMEWORK IN DEVELOPING ECONOMIES
3.3. MARKET OPPORTUNITIES
3.3.1. INCREASING RESEARCH ON HUMAN CLINICAL TRIALS
3.3.2. RISING DEMAND OF GENE THERAPY
3.3.3. EASY STORAGE CAN BE BENEFICIAL IN DEVELOPING COUNTRIES 
3.4.  MARKET CHALLENGES 
3.4.1. LACK OF AWARENESS TOWARDS GENE BASED VACCINATIONS
3.4.2. MANUFACTURING A SAFE AND EFFECTIVE PRODUCT WITH LESS SIDE EFFECTS
 
4. MARKET SEGMENTATION 
4.1. GLOBAL DNA VACCINES MARKET BY TYPE
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION 
4.1.5.1. GLOBAL ANIMAL DNA VACCINES MARKET
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.2. GLOBAL HUMAN DNA VACCINES MARKET 
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.2.4. KEY CONCLUSIONS
4.1.5.2.5. KEY CONCLUSIONS
4.2. GLOBAL DNA VACCINES MARKET BY TECHNOLOGY
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION 
4.2.5.1. GLOBAL PLASMID DNA VACCINES TECHNOLOGY MARKET
4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.4. KEY CONCLUSIONS
4.2.5.2. GLOBAL PLASMID DNA DELIVERY TECHNOLOGY MARKET 
4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.4. KEY CONCLUSIONS
4.3. GLOBAL DNA VACCINES MARKET BY APPLICATIONS
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION 
4.3.5.1. GLOBAL HUMAN DISEASES APPLICATIONS MARKET
4.3.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.3.5.1.4. KEY CONCLUSIONS
4.3.5.1.5. SUBSEGMENTS
4.3.5.1.5.1. ONCOLOGY
4.3.5.1.5.2. INFECTIOUS DISEASE
4.3.5.1.5.3. ALLERGIES
4.3.5.1.5.4. OTHERS
4.3.5.2. GLOBAL VETERINARY DISEASES APPLICATIONS MARKET 
4.3.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.3.5.2.4. KEY CONCLUSIONS
4.3.5.2.5. SUB SEGMENTS
4.3.5.2.5.1. CANINE MELANOMA
4.3.5.2.5.2. LEISHMANIASIS
4.3.5.2.5.3. EQUINE WEST NILE VIRUS
4.3.5.2.5.4. OTHERS
 
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS & ACQUISITION 
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
 
6. GLOBAL DNA VACCINES MARKET BY REGION 
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GEOGRAPHIC SEGMENTATION
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY APPLICATION ANALYSIS
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S. 
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY APPLICATION ANALYSIS
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY APPLICATION ANALYSIS
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY APPLICATION ANALYSIS
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA 
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
 
7. COMPANY PROFILES
7.1. NOVARTIS ANIMAL HEALTH
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION/FOCUS SECTOR
7.1.4. STRATEGIC INITIATIVES 
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2. INOVIO BIOMEDICAL CORP
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION/FOCUS SECTOR
7.2.4. STRATEGIC INITIATIVES 
7.2.5. SCOT ANALYSIS 
7.2.6. STRATEGIC ANALYSIS
7.3. MERCK & CO.
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION/FOCUS SECTOR
7.3.4. STRATEGIC INITIATIVES 
7.3.5. SCOT ANALYSIS 
7.3.6. STRATEGIC ANALYSIS
7.4. DENDREON CORPORATION
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION/FOCUS SECTOR
7.4.4. STRATEGIC INITIATIVES 
7.4.5. SCOT ANALYSIS 
7.4.6. STRATEGIC ANALYSIS
7.5. ASTELLAS PHARMA
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION/FOCUS SECTOR
7.5.4. STRATEGIC INITIATIVES 
7.5.5. SCOT ANALYSIS
7.5.6. STRATEGIC ANALYSIS
7.6. VICAL
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION/FOCUS SECTOR
7.6.4. STRATEGIC INITIATIVES 
7.6.5. SCOT ANALYSIS
7.6.6. STRATEGIC ANALYSIS
7.7. SANOFI
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION/FOCUS SECTOR
7.7.4. STRATEGIC INITIATIVES 
7.7.5. SCOT ANALYSIS 
7.7.6. STRATEGIC ANALYSIS
7.8.   TEKMIRA PHARMACEUTICALS
7.8.1. OVERVIEW 
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION/FOCUS SECTOR
7.8.4. STRATEGIC INITIATIVES 
7.8.5. SCOT ANALYSIS
7.8.6. STRATEGIC ANALYSIS
7.9. GLAXOSMITHKLINE INC.
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION/FOCUS SECTOR
7.9.4. STRATEGIC INITIATIVES 
7.9.5. SCOT ANALYSIS
7.9.6. STRATEGIC ANALYSIS
7.10.  PFIZER PHARMACEUTICALS
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION/FOCUS SECTOR
7.10.4. STRATEGIC INITIATIVES 
7.10.5. SCOT ANALYSIS
7.10.6. STRATEGIC ANALYSIS
7.11.  ADVANCE BIOSCIENCE LABORATORIES INC.
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION/FOCUS SECTOR
7.11.4. STRATEGIC INITIATIVES 
7.11.5. SCOT ANALYSIS
7.11.6. STRATEGIC ANALYSIS
7.12. INDIAN IMMUNOLOGICALS LTD.
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION/FOCUS SECTOR
7.12.4. STRATEGIC INITIATIVES 
7.12.5. SCOT ANALYSIS
7.12.6. STRATEGIC ANALYSIS
7.13.  XENETIC BIOSCIENCES INC.
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION/FOCUS SECTOR
7.13.4. STRATEGIC INITIATIVES 
7.13.5. SCOT ANALYSIS 
7.13.6. STRATEGIC ANALYSIS
7.14. QED BIOSCIENCES INC.
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION/FOCUS SECTOR
7.14.4. STRATEGIC INITIATIVES 
7.14.5. SCOT ANALYSIS
7.14.6. STRATEGIC ANALYSIS
7.15. TOLERION INC. 
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION/FOCUS SECTOR
7.15.4. STRATEGIC INITIATIVES 
7.15.5. SCOT ANALYSIS
7.15.6. STRATEGIC ANALYSIS
 
LIST OF TABLES
 
1. GLOBAL DNA VACCINES MARKET BY TYPE 2014-2023 ($ MILLION)
2. GLOBAL ANIMAL DNA VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
3. GLOBAL HUMAN DNA VACCINES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
4. GLOBAL DNA VACCINES MARKET BY TECHNOLOGY 2014-2023 ($ MILLION)
5. GLOBAL PLASMID DNA VACCINES TECHNOLOGY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
6. GLOBAL PLASMID DNA DELIVERY TECHNOLOGY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
7. GLOBAL DNA VACCINES MARKET BY APPLICATIONS 2014-2023 ($ MILLION)
8. GLOBAL HUMAN DISEASES APPLICATIONS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
9. GLOBAL VETERINARY DISEASES APPLICATIONS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
10. NORTH AMERICA DNA VACCINES MARKET 2014-2023 ($ MILLION)
11. EUROPE DNA VACCINES MARKET 2014-2023 ($ MILLION)
12. ASIA PACIFIC DNA VACCINES MARKET 2014-2023 ($ MILLION)
13. REST OF THE WORLD DNA VACCINES MARKET 2014-2023 ($ MILLION)
 
LIST OF FIGURES
 
1. GLOBAL ANIMAL DNA VACCINES MARKET 2014-2023 ($ MILLION)
2. GLOBAL HUMAN DNA VACCINES MARKET  2014-2023 ($ MILLION)
3. GLOBAL PLASMID DNA VACCINES TECHNOLOGY MARKET 2014-2023 ($ MILLION)
4. GLOBAL PLASMID DNA DELIVERY TECHNOLOGY MARKET 2014-2023 ($ MILLION)
5. GLOBAL HUMAN DISEASES APPLICATIONS MARKET  2014-2023 ($ MILLION)
6. GLOBAL VETERINARY DISEASES APPLICATIONS MARKET 2014-2023 ($ MILLION)
7. UNITED STATES (U.S.) DNA VACCINES MARKET 2014-2023 ($ MILLION)
8. CANADA DNA VACCINES MARKET 2014-2023 ($ MILLION)
9. UNITED KINGDOM (UK) DNA VACCINES MARKET 2014-2023 ($ MILLION)
10. FRANCE DNA VACCINES MARKET 2014-2023 ($ MILLION)
11. GERMANY DNA VACCINES MARKET 2014-2023 ($ MILLION)
12. SPAIN DNA VACCINES MARKET 2014-2023 ($ MILLION)
13. ITALY DNA VACCINES MARKET 2014-2023 ($ MILLION)
14. ROE DNA VACCINES MARKET 2014-2023 ($ MILLION)
15. INDIA DNA VACCINES MARKET 2014-2023 ($ MILLION)
16. CHINA DNA VACCINES MARKET 2014-2023 ($ MILLION)
17. JAPAN DNA VACCINES MARKET 2014-2023 ($ MILLION)
18. KOREA DNA VACCINES MARKET 2014-2023 ($ MILLION)
19. AUSTRALIA DNA VACCINES MARKET 2014-2023 ($ MILLION)
20. ROAPAC DNA VACCINES MARKET 2014-2023 ($ MILLION)
21. LATIN AMERICA DNA VACCINES MARKET 2014-2023 ($ MILLION)
22. MENA DNA VACCINES MARKET 2014-2023 ($ MILLION)
 

FAQ

How can I purchase a report?
We offer an easy way to purchase any report of your choice from various domains that we offer. You can easily search for your desired reports by simply using the search bar on our website's home page. For multiple purchases, you can add reports to the shopping cart, fill a detail form and check out. We accept payments though authentic and trusted payment gateways which accept all major credit cards.
How safe is to use my credit card? Is my information secure?
We ensure complete safety to all online transactions made by credit cards. We use most secure encryption technology available today for the electronic transactions and all our credit card sales are secured with an SSL technology. Your information is highly secure and confidential.
Can I get a discount?
We send discount offers through email as per your request. In case you would like to receive discounts, please sign up for our newsletter.
I want to buy only a chapter. I don't need complete report.
Yes you can buy your desired chapter/page or the entire report, by just clicking on the table of contents in any report and selecting chapter of your interest. We do have separate pricing for chapters/reports/excel sheets/presentation pages etc.
Can I get reports on my desired topic specially which is not available in your current portfolio?
Do call us or mail us the topic of your preference. Our dedicated team on analysts will prepare a report as per your preference and requirements.
When do I get access to the report(s) that I have purchased?
We will email you your purchased report right after we receive your payment through any of the payment options.
Will I receive any invoice for my purchase?
Yes we will email you invoice/payment confirmation with the order details once we receive your payment.
In what format will the reports be available in?
All the reports will be available in PDF format for download.

Request for Sample
Select License Type
Required More Information

0731 4042636

+91 9713031393

UPCOMING REPORTS

No upcoming reports available under this subcategory.

NAVIGATION LINK

OUR SERVICES

credit card

CONNECT WITH US

Occams Business Research & Consulting Pvt. Ltd.

Landline: 0731 4042636 

Handheld: +91 9713031393

Email: [email protected]

 

 

  • facebook
  • twitter
  • blog
  • linkdin
  • google plus
  • youtube
Go To Top
viewthroughconversion